1. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta neuropathologica. 2016;131(6):803-20.
2. deSouza RM, Shaweis H, Han C, et al. Has the survival of patients with glioblastoma changed over the years? British journal of cancer. 2016;114(2):146-50.
3. Marenco-Hillembrand L, Wijesekera O, Suarez-Meade P, et al. Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis. Journal of Neuro-Oncology. 2020;147(2):297-307.
4. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-96.
5. Leven C, Padelli M, Carré JL, Bellissant E, Misery L. Immune Checkpoint Inhibitors in Melanoma: A Review of Pharmacokinetics and Exposure-Response Relationships. Clinical pharmacokinetics. 2019;58(11):1393-405.
6. Muftuoglu Y, Liau LM. Results From the CheckMate 143 Clinical Trial: Stalemate or New Game Strategy for Glioblastoma Immunotherapy? JAMA Oncology. 2020;6(7):987-9.
7. Ville S, Poirier N, Blancho G, Vanhove B. Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells? 2015;6(411).
8. Trombetta AC, Soldano S, Contini P, et al. A circulating cell population showing both M1 and M2 monocyte/macrophage surface markers characterizes systemic sclerosis patients with lung involvement. Respir Res. 2018;19(1):186.
9. Uhlén M, Fagerberg L, Hallström BM, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.
10. Hersey P, Si Z, Smith MJ, Thomas WD. Expression of the co-stimulatory molecule B7 on melanoma cells. International journal of cancer. 1994;58(4):527-32.
11. Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. 2018;8(9):1069-86.
12. Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58-67.
13. Letendre P, Monga V, Milhem M, Zakharia Y. Ipilimumab: from preclinical development to future clinical perspectives in melanoma. Future oncology (London, England). 2017;13(7):625-36.
14. Savoia P, Astrua C, Fava P. Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management. Human vaccines & immunotherapeutics. 2016;12(5):1092-101.
15. Nduom EK, Wei J, Yaghi NK, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro-oncology. 2016;18(2):195-205.
16. Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: an open-source platform for biological-image analysis. Nature methods. 2012;9(7):676-82.
17. Vessières A, Quissac E, Lemaire N, et al. Heterogeneity of Response to Iron-Based Metallodrugs in Glioblastoma Is Associated with Differences in Chemical Structures and Driven by FAS Expression Dynamics and Transcriptomic Subtypes. Int J Mol Sci. 2021;22(19).
18. Zhou R, Zeng D, Zhang J, et al. A robust panel based on tumour microenvironment genes for prognostic prediction and tailoring therapies in stage I–III colon cancer. EBioMedicine. 2019;42:420-30.
19. Li S, Chen S, Wang B, Zhang L, Su Y, Zhang X. A Robust 6-lncRNA Prognostic Signature for Predicting the Prognosis of Patients With Colorectal Cancer Metastasis. 2020;7(56).
20. Greenbaum D, Colangelo C, Williams K, Gerstein M. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biology. 2003;4(9):117.
21. van Nieuwenhuijze A, Liston A. The Molecular Control of Regulatory T Cell Induction. Progress in molecular biology and translational science. 2015;136:69-97.
22. Fang J, Chen F, Liu D, Gu F, Chen Z, Wang Y. Prognostic value of immune checkpoint molecules in breast cancer. Bioscience reports. 2020;40(7).
23. Feng XY, Lu L, Wang KF, et al. Low expression of CD80 predicts for poor prognosis in patients with gastric adenocarcinoma. Future oncology (London, England). 2019;15(5):473-83.
24. Chang CS, Chang JH, Hsu NC, Lin HY, Chung CY. Expression of CD80 and CD86 costimulatory molecules are potential markers for better survival in nasopharyngeal carcinoma. BMC cancer. 2007;7:88.
25. Wang Z, Zhang C, Liu X, et al. Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. Oncoimmunology. 2016;5(11):e1196310.
26. Gavile CM, Barwick BG, Newman S, et al. CD86 regulates myeloma cell survival. Blood advances. 2017;1(25):2307-19.
27. Qiu H, Li Y, Cheng S, Li J, He C, Li J. A Prognostic Microenvironment-Related Immune Signature via ESTIMATE (PROMISE Model) Predicts Overall Survival of Patients With Glioma. Front Oncol. 2020;10(2556):580263.
28. Berghoff AS, Kiesel B, Widhalm G, et al. Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro-oncology. 2017;19(11):1460-8.
29. Zhang J, Sai K, Wang Xl, et al. Tim-3 Expression and MGMT Methylation Status Association With Survival in Glioblastoma. 2020;11(1478).
30. Pratt D, Dominah G, Lobel G, et al. Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma. Neurosurgery. 2019;85(2):280-9.
31. Qiu H, Tian W, He Y, et al. Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma. Front Oncol. 2021;11:654350.